pharma · Hypoparathyroidism · Postbariatric Hypoglycemia · MBX
MBX Biosciences
MBX Biosciences is a pharma organization headquartered in Carmel, USA. It trades on NYSE under ticker MBX. Primary therapeutic focus areas include Hypoparathyroidism, Postbariatric Hypoglycemia, Renal Impairment, Obesity
Carmel, USA HQ
2019 Founded
74 Employees
Public company Type
MBX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Carmel, USA
- Founded
- 2019
- Employees
- 74
- Programs
- 7
- Drugs
- 3
- Patents
- 0
400 µg of MBX 2109 once-weekly by subcutaneous injection
Phase 2 · small molecule · Hypoparathyroidism
400 µg of MBX 2109 once-weekly by subcutaneous injection for Hypoparathyroidism is a Phase 2 program (small_molecule) at MBX Biosciences with 1 ClinicalTrials.gov record(s).
Internal code MBX-2H1004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MBX Biosciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Hypoparathyroidism
- Status
- active
- Trials
- 1